Health ❯ Healthcare ❯ Cancer Treatment

Targeted Therapy

Antibody Drug Conjugates EGFR Inhibitors Menin Inhibitors Drug Approval NSD2 Inhibition XPO1 Protein HER2+ Therapy Viral Mimics FLT3-ITD Mutation EGFR Tyrosine Kinase Inhibitors

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

Early trial results point to a possible targeted option for KRAS G12D lung cancer pending confirmation in larger studies.

CD70-Targeted HIT Cells Eradicate Solid Tumors in Mice

Waterloo Scientists Ready Engineered Tumor‑Eating Bacteria for Preclinical Testing

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Japan's 54,000-Patient Cancer Panel Study Finds Many Targets, Few Treatments

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

Enhertu Delivers Pivotal Gains in Early HER2-Positive Breast Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Niraparib Add-On Slows Progression in Advanced Prostate Cancer, Phase III Trial Shows

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

Preclinical PET Tracer Enables Same-Day Imaging of Nectin-4 in Breast and Bladder Cancers

FAP-Targeted Radioligand Yields Near-Complete Response in Three Solitary Fibrous Tumor Patients

Lung Tumors Reprogram Bone Marrow Progenitors as NRF2 Emerges as a Target

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort